March 20196Copyright © 2019 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.MARCH - 28 - 2019VOLUME 02 - 04HAEMATOLOGY SPECIALContact UsPhone:510 230 0396 Fax:510-894-8405Emailsales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comManaging EditorAlex D'souzaEditorial StaffSalesDan StanleyJoe PhilipLaura PintoMatthew JacobMerlin WatsonSinchana NageshVisualizerSujith MAndrew Smithandrew@medicaltechoutlook.com510.996.5123Alex D'souzaManaging Editoreditor@Medicaltechoutlook.comThe Future of Orthopedics is Here*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditorialPublished by ValleyMedia Inc. To subscribe to MedicalTech OutlookVisit www.Medicaltechoutlook.com A medical mystery of its time, studying the nature and complexity of blood is still very much the focus of the modern medical researcher. However, hematology in 2019 was less academia and more in line with addressing long stagnant diseases. One particularly innovative one, regarding sickle cell anemia, called HemoTypeSC, uses monoclonal antibodies to detect hemoglobins A, S, and C in a drop of whole blood.The past year thus saw what can now be called "An inexpensive, rapid, and easy-to-use blood test, which was more than 99% accurate in detecting sickle cell disease in young children in sub-Saharan Africa," according to research reported at the annual meeting of the American Society of Hematology.Additionally, several targeted therapies (e.g., ibrutinib, venetoclax) are available for relapsed or refractory chronic lymphocytic leukemia (CLL), and others are being evaluated. In a trial of 319 patients with relapsed or refractory CLL, the PI3K inhibitor duvelisib improved response rates and progression-free survival relative to the anti-CD20 antibody ofatumumab, including for those with 17p deletion and/or TP53 mutation. This led to its approval by the US Food and Drug Administration early last year.Instrumental in hematological diagnoses, Mass spectrometry (MS) is an investigational method that uses high-resolution molecular mass measurements to accurately identify and classify M-proteins in the serum. In addition to being more accurate than immunofixation, initial reports suggest that, unlike other methods, MS is also able to accurately discriminate between therapeutic monoclonal antibodies (e.g., daratumumab) and endogenous M-proteins. While some research institutions are replacing immunofixation with MS, few clinical laboratories are able to conduct MS testing, and as such, MS is not yet a standard part of the evaluation of M-proteins in most medical centers. As always, to bring clarity into and map this ever expanding space, MedTech Outlook proudly presents to you its special edition on sales management trends and solutions. We hope the valuable insights from practitioners, industry thought leaders, and the cutting edge solutions from leading, as well as emerging companies featured in this edition will help you in making informed decisions for your institution.Let us know you thoughts.Ahead of Diagnostic Advancements in Blood
< Page 5 | Page 7 >